Latest News
Conference Coverage
Enzalutamide shines in nonmetastatic castration-resistant prostate cancer
SAN FRANCISCO - Metastasis-free survival was 36.6 months with enzalutamide and 14.7 months with placebo.
Latest News
Study explores biological implications of MHC-II expression in tumor cells
SAN FRANCISCO – MHC-II expression could be useful for stratifying patients to combined anti-PD-1/anti-LAG-3 therapy, and eventually to anti-PD-1/...
Feature
Transparency lacking in oncology clinical pathways
Health plans are under fire for the hidden conflicts of interest in their clinical pathway panels.
Latest News
USPSTF: Routine screens for ovarian cancer not recommended
USPSTF issues final recommendation against routine screens, citing risk for unnecessary surgeries.
From the Journals
FIRST trial analysis shows more benefit for lenalidomide
The FIRST trial evaluates treatment options for patients with newly-diagnosed multiple myeloma who are not eligible for transplant.
Conference Coverage
Bladder cancer: Two chemoradiation therapy regimens on par for muscle-invasive disease
Primary results were comparable in the NRG/RTOG 0712 trial, but one regimen is more convenient.
Conference Coverage
ERV expression may predict response to immune checkpoint blockade in ccRCC, other solid tumors
ERV expression may be associated with immune checkpoint pathway activation and response to immune checkpoint therapy in ccRCC.
Conference Coverage
Promising outcomes of thrombolysis for caval extension of iliofemoral DVT
CHICAGO – Acute caval involvement predicts reduced risk of postthrombotic syndrome.
From the Journals
Melanoma incidence increased in older non-Hispanic whites
Skin cancer prevention efforts, which appear to have had an effect among young people, now need to target the older generation.
Conference Coverage
Getting hematologic cancer drugs on the fast track
In 2017, the FDA approved 17 agents for new or expanded indications for hematologic malignancies, including one agent for anaplastic large cell...
Conference Coverage
T-cell lymphoma therapies on the horizon
LA JOLLA, CALIF. – Three new agents are in the pipeline for T-cell lymphoma.